An Exploratory Analysis of Immune and Inflammatory Response Associated With Clozapine

Inclusion Criteria: * All participants: * Between 18 and 65 years of age * Physically healthy (no clinically significant unstable medical condition as confirmed by medical history and physical examination) * Able to give informed consent * Treatment-Refractory Schizophrenia Clozapine treatment group (n = 30) Individuals treated with Clozapine consistently for a minimum of 6 months Non-Clozapine treatment group Continued treatment with non-Clozapine antipsychotic but would be eligible for Clozapine with the provider/patient electing to not pursue such for clinical reasons, consistently treated for at least 6 months Exclusion Criteria: * Clinically significant medical condition; cardiovascular, pulmonary, endocrine, or renal condition requiring in depth medical treatment * Active or recent (within 4 weeks) bacterial or viral infection * Chronic viral infection (hepatitis, HIV) * History of autoimmune, or chronic inflammatory condition * Current treatment with lithium * Treatment with Clozapine in the past 6 months * Current treatment with immunomodulatory or anti-inflammatory therapy * Vaccination within the past 3 months * Current alcohol or substance use disorder of moderate or severe severity * Intellectual disability (i.e. intelligence quotient \<70) * Unwilling or unable to sign informed consent document * Pregnancy * Any patient deemed ineligible by PI discretion